

EV 133105695 US

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. VOS-14 CON	APPLN. NO. Not yet assigned
	APPLICANT Leszek Wojnowski et al.	CONFIRMATION NO. Not yet assigned
	FILING DATE Concurrently Herewith	GROUP Not yet assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
/J.G./	WO 98/24914	06/11/98	PCT				
/J.G./	WO 98/44939	10/15/98	PCT				
/J.G./	WO 00/39332	07/06/00	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
/J.G./	Hustert, E. et al., "The Genetic Determinants of the CYP3A5 Polymorphism," <i>Pharmacogenetics</i> 11:773-779 (2001).
/J.G./	Paulussen, A. et al., "Two Linked Mutations in Transcriptional Regulatory Elements of the CYP3A5 Gene Constitute the Major Genetic Determinant of Polymorphic Activity in Humans," <i>Pharmacogenetics</i> 10:415-424 (2000).

EXAMINER

/Jaime Greene/

DATE CONSIDERED

10/14/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

EV 133105695 US

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
VOS-14 CONAPPLN. NO.
Not yet assignedINFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Leszek Wojnowski et al.CONFIRMATION NO.
Not yet assignedFILING DATE
Concurrently HerewithGROUP
Not yet assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/24914	06/11/98	PCT				
	WO 98/44939	10/15/98	PCT				
	WO 00/39332	07/06/00	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Hustert, E. et al., "The Genetic Determinants of the CYP3A5 Polymorphism." <i>Pharmacogenetics</i> 11:773-779 (2001).
	Paulussen, A. et al., "Two Linked Mutations in Transcriptional Regulatory Elements of the CYP3A5 Gene Constitute the Major Genetic Determinant of Polymorphic Activity in Humans." <i>Pharmacogenetics</i> 10:415-424 (2000).

EXAMINER

/Jalme Greene/

DATE CONSIDERED 10/14/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
Sheet	1	of	1	Application Number	10/607,596
				Filing Date	June 27, 2003
				First Named Inventor	Leszek Wojnowski et al.
				Art Unit	1645
				Examiner Name	Not yet assigned
				Attorney Docket Number	VOS-14 CON

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁴
		Country Code ³ - Number ² - Kind Code ⁵				
/J.G./		WO 98/44939	10/15/1998	Merck & Co, Inc.		
/J.G./		WO 00/47771	08/17/2000	Genset		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	† ⁴
/J.G./		Hustert, E. et al., "The genetic determinants of the CYP3A5 polymorphism," <i>Pharmacogenetics</i> 11:773-779 (2001).	
/J.G./		Paulussen, A. et al., "Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans," <i>Pharmacogenetics</i> 10:415-424 (2000).	

Examiner Signature	/Jaime Greene/	Date Considered	10/14/2007
-----------------------	----------------	--------------------	------------

All References Have Been Considered: _____
Examiner

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.